What's in Ache Laboratorios Farmaceuticos S.A.'s pipeline?

Ache Laboratorios Farmaceuticos S.A. has 17 drugs in our index: 8 marketed, 0 filed, 9 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Ache Laboratorios Farmaceuticos S.A.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Boryung Pharmaceutical Co., Ltd, Ahn-Gook Pharmaceuticals Co.,Ltd, Astellas Pharma Inc, Bausch Health Americas, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ache-laboratorios-farmaceuticos-s-a.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Ache Laboratorios Farmaceuticos S.A. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ache Laboratorios Farmaceuticos S.A. pipeline: 8 marketed, 0 filed, 9 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

8 marketed 0 filed 9 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Brompheniramine + pseudoephedrine	Brompheniramine + pseudoephedrine	marketed	Antihistamine + decongestant combination	H1 receptor (brompheniramine); alpha-1 adrenergic receptor (pseudoephedrine)	Allergy/Immunology
Recombinant human growth hormone - Hormotrop	Recombinant human growth hormone - Hormotrop	marketed
Recombinant human growth hormone - Biomatrop	Recombinant human growth hormone - Biomatrop	marketed
Nizoral®	Nizoral®	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)	Infectious Disease
Motore	Motore	marketed			Other
brompheniramine + phenylephrine	brompheniramine + phenylephrine	marketed	Antihistamine + decongestant combination	H1 receptor (brompheniramine); alpha-1 adrenergic receptor (phenylephrine)	Allergy/Immunology
Canesten®	Canesten®	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)	Infectious Disease
DNN.22.17.036	DNN.22.17.036	marketed			Other
Product CM9241GRU	Product CM9241GRU	phase 3	ACE inhibitor	ACE	Cardiovascular
Candicort®	Candicort®	phase 3	Topical corticosteroid	Glucocorticoid receptor	Dermatology
Product DNN.65.21.005	Product DNN.65.21.005	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
Cosamin DS®	Cosamin DS®	phase 3	Nutraceutical/Dietary supplement		Rheumatology/Orthopedics

Therapeutic area mix

Allergy/Immunology · 2
Dermatology · 2
Infectious Disease · 2
Other · 2
Rheumatology/Orthopedics · 2
Urology · 1
Cardiovascular · 1
Pain/Inflammation (as control for Voltaren) · 1
Diabetes · 1
Rheumatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 3 shared drug classes
Boryung Pharmaceutical Co., Ltd · 2 shared drug classes
Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
Astellas Pharma Inc · 2 shared drug classes
Bausch Health Americas, Inc. · 2 shared drug classes
Bayer · 2 shared drug classes
Ain Shams University · 2 shared drug classes
AstraZeneca · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Ache Laboratorios Farmaceuticos S.A.:

Cite this brief

Drug Landscape (2026). Ache Laboratorios Farmaceuticos S.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ache-laboratorios-farmaceuticos-s-a. Accessed 2026-05-16.